Drug intelligence / Profile preview

IGFBP2 peptides

Development stage
Preclinical
Lead developer
Biostax
Modality
Peptides, Vaccines & Immunotherapeutics
Administration
Intradermal, Intravenous, Subcutaneous
01

Overview

IGFBP2 peptides refer to a class of peptide therapeutics and vaccine candidates derived from insulin-like growth factor-binding protein 2 (IGFBP-2). These peptides are being developed for several distinct therapeutic applications. In oncology, researchers at the University of Washington have developed a multi-peptide cancer vaccine consisting of three MHC class II-restricted IGFBP-2 peptides (p8-22, p251-265, and p291-305) designed to stimulate Type I CD4+ T-helper (Th1) cell-mediated immune responses against IGFBP-2-overexpressing tumors, such as breast and ovarian cancers. In neurology, Northwestern University researchers developed JB2, an IGFBP2-mimetic peptide fragment that promotes synaptic plasticity and is being investigated for Phelan-McDermid syndrome and autism spectrum disorder. Additionally, Alizé Pharma has investigated IGFBP-2-derived peptides with bone anabolic properties for the treatment of osteoporosis and other bone diseases.

Other names
IGFBP-2 peptide vaccineIGFBP2 peptide vaccineIGFBP 2 peptide vaccineIGFBP-2 peptidesIGFBP2 peptidesIGFBP 2 peptidesJB2JB-2JB 2
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)IGFBP2 (Insulin-like growth factor binding protein II)IGF2R (Cation-independent mannose-6-phosphate receptor)

Beyond the preview

Go deeper on IGFBP2 peptides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGFBP2 peptides.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call